Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bhardwaj, S.
Right arrow Articles by Holland, J.F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bhardwaj, S.
Right arrow Articles by Holland, J.F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 1:443-444, 1990
© 1990 European Society for Medical Oncology

brief-report

Short report: A pilot trial of TMM (Thiotepa, Mitoxantrone and Methotrexate) chemotherapy for metastatic breast cancer

S. Bhardwaj and J.F. Holland

Department of Neoplastic Diseases, Derald H. Ruttenberg Cancer Center at Mount Sinai, Mount Sinai Medical Center New York, USA

Correspondence to: Sushil Bhardwaj, M.D., Box 1129, Mount Sinai, Medical Center, One Gustave Levy Place, New Yorfc, N.Y. 10029, U.S.A.

The maximum tolerated dose for a combination chemotherapy regimen of Thiotepa, Mitoxantrone and Methotrexate (TMM) administered intravenously every three weeks to twelve patients with metastatic breast cancer was: Thiotepa: 15mg/m2, Mitoxantrone: 10mg/m2 and Methotrexate: 30mg/m2. The major toxicities from the combination related to myelosuppression. Partial response was seen in 5 patients, ranging in duration from 1.25 to 10 months. Four out of eight patients who had received prior doxorubicin responded. The results are encouraging and warrant further study of this combination.

Combination chemotherapy, Thiotepa, Mitoxantrone and Methotrexate, TMM, metastatic breast cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.